Walgreens Boots Alliance (WBA)
(Delayed Data from NSDQ)
$8.74 USD
+0.09 (1.04%)
Updated Sep 5, 2024 04:00 PM ET
After-Market: $8.73 -0.01 (-0.11%) 5:12 PM ET
5-Strong Sell of 5 5
D Value D Growth A Momentum C VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$8.74 USD
+0.09 (1.04%)
Updated Sep 5, 2024 04:00 PM ET
After-Market: $8.73 -0.01 (-0.11%) 5:12 PM ET
5-Strong Sell of 5 5
D Value D Growth A Momentum C VGM
Zacks News
Walgreens Boots Alliance (WBA) Dips More Than Broader Markets: What You Should Know
by Zacks Equity Research
In the latest trading session, Walgreens Boots Alliance (WBA) closed at $37.58, marking a -1.91% move from the previous day.
Walgreens Boots Alliance (WBA) Stock Moves -0.41%: What You Should Know
by Zacks Equity Research
In the latest trading session, Walgreens Boots Alliance (WBA) closed at $38.44, marking a -0.41% move from the previous day.
Walgreens Boots (WBA) Gains From Digital Sales Amid Cost Woes
by Zacks Equity Research
Within the U.S. Healthcare segment, Walgreens Boots (WBA) is optimistic about the acquisition of CareCentrix.
Rite Aid (RAD) Reports Q3 Loss, Tops Revenue Estimates
by Zacks Equity Research
Rite Aid (RAD) delivered earnings and revenue surprises of 56.25% and 2.46%, respectively, for the quarter ended November 2022. Do the numbers hold clues to what lies ahead for the stock?
Walgreens Boots Alliance (WBA) Gains As Market Dips: What You Should Know
by Zacks Equity Research
Walgreens Boots Alliance (WBA) closed at $39.32 in the latest trading session, marking a +0.69% move from the prior day.
ETF Market Outlook & Investing Strategies for 2023
by Neena Mishra
We discuss the market outlook and investing strategies for 2023.
Top Research Reports for Verizon, Honeywell & CVS Health
by Sheraz Mian
Today's Research Daily features new research reports on 16 major stocks,including Verizon Communications Inc. (VZ), Honeywell International Inc. (HON) and CVS Health Corporation (CVS).
Here's Why You Should Retain Walgreens Boots (WBA) For Now
by Zacks Equity Research
Investors are optimistic about Walgreens Boots (WBA) led by strategic collaborations and noteworthy product launches.
Walgreens Boots Alliance (WBA) Outpaces Stock Market Gains: What You Should Know
by Zacks Equity Research
Walgreens Boots Alliance (WBA) closed the most recent trading day at $41.06, moving +1.56% from the previous trading session.
AmerisourceBergen (ABC) to Repurchase Common Stock Worth $200M
by Zacks Equity Research
AmerisourceBergen (ABC) announces a share repurchase worth $200 million in concurrence with the sale of its shares by one of its shareholders, Walgreens Boots Alliance, under Rule 144.
Walgreens Boots Alliance (WBA) Stock Moves -0.65%: What You Should Know
by Zacks Equity Research
Walgreens Boots Alliance (WBA) closed at $41.21 in the latest trading session, marking a -0.65% move from the prior day.
Walgreens Boots Alliance (WBA) Gains As Market Dips: What You Should Know
by Zacks Equity Research
Walgreens Boots Alliance (WBA) closed at $41.08 in the latest trading session, marking a +0.66% move from the prior day.
Walgreens Boots Alliance (WBA) Stock Sinks As Market Gains: What You Should Know
by Zacks Equity Research
Walgreens Boots Alliance (WBA) closed the most recent trading day at $41.76, moving -0.07% from the previous trading session.
Is First Trust Consumer Staples AlphaDEX ETF (FXG) a Strong ETF Right Now?
by Zacks Equity Research
Smart Beta ETF report for FXG
Should You Invest in the First Trust Consumer Staples AlphaDEX ETF (FXG)?
by Zacks Equity Research
Sector ETF report for FXG
Zacks Market Edge Highlights: WBA, TROW, ITW, NUS, WSM
by Zacks Equity Research
WBA, TROW, ITW, NUS and WSM have been highlighted in this Market Edge article.
Looking for High Yields? Check the Dividend Aristocrats
by Tracey Ryniec
Getting a 5% yield isn't easy but here's some tips for finding the stocks.
Walgreens Boots Alliance (WBA) Dips More Than Broader Markets: What You Should Know
by Zacks Equity Research
Walgreens Boots Alliance (WBA) closed the most recent trading day at $40.54, moving -1.75% from the previous trading session.
Company News for Nov 14, 2022
by Zacks Equity Research
Companies in The News Are: WBA, AMZN, COIN, AQN
Should Investors Buy CVS Stock Before Q3 Earnings?
by Shaun Pruitt
Trading 15% from its highs, CVS (CVS) is set to report Q3 earnings on Wednesday, November 2. Investors hope the company can capitalize on its ambition to sustain itself as an industry leader as the Retail-Pharmacies Drug Stores Industry is currently in the top 18% of over 250 Zacks Industries.
Online Strength to Drive Rite Aid (RAD) Amid Supply-Chain Woes
by Zacks Equity Research
Rite Aid (RAD) remains well-placed on online strength, increased non-COVID prescriptions and cost initiatives despite muted COVID-19 testing and vaccine demand, and supply-chain issues.
Zacks Industry Outlook Highlights CVS Health, Walgreens Boots Alliance, Rite Aid and Amazon's
by Zacks Equity Research
CVS Health, Walgreens Boots Alliance, Rite Aid and Amazon's are part of Zacks Industry Outlook article.
3 Retail Pharmacy and Drugstore Stocks to Watch Amid Industry Challenges
by Urmimala Biswas
The Zacks Retail Pharmacy and Drugstore industry players like CVS, WBA and RAD are likely to gain from the growing demand for digital healthcare support. However, reimbursement challenges are hurting overall industry health.
Walgreens Boots (WBA) Q4 Earnings Top, Operating Loss Concerns
by Zacks Equity Research
The U.S. Healthcare segment of Walgreens Boots (WBA) grows on key contract wins, continued partnership growth and a strong focus on execution.
Walgreens Boots Alliance (WBA) Beats Q4 Earnings Estimates
by Zacks Equity Research
Walgreens (WBA) delivered earnings and revenue surprises of 2.56% and 0.13%, respectively, for the quarter ended August 2022. Do the numbers hold clues to what lies ahead for the stock?